Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 182

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia

Treon, Steven P., Gustine, Joshua, Meid, Kirsten, Yang, Guang, Xu, Lian, Liu, Xia, Demos, Maria, Kofides, Amanda, Tsakmaklis, Nicholas, Chen, Jiaji G., Munshi, Manit, Chan, Gloria, Dubeau, Toni, Raje, Noopur, Yee, Andrew, O’Donnell, Elizabeth, Hunter, Zachary R., Castillo, Jorge J. · 2018 · Journal of Clinical Oncology

Abstract

Purpose: Ibrutinib is active in previously treated Waldenström macroglobulinemia (WM). MYD88 mutations ( MYD88 MUT) and CXCR4 mutations ( CXCR4 MUT) affect ibrutinib response. We report on a prospective study of ibrutinib monotherapy in symptomatic, untreated patients with WM, and the effect of CXCR4 MUT status on outcome. Patients and Methods: Symptomatic, treatment-naïve patients with WM were eligible. Ibrutinib (420 mg) was administered daily until progression or unacceptable toxicity. All tumors were genotyped for MYD88 MUT and CXCR4 MUT. Results: A total of 30 patients with WM received ibrutinib. All carried MYD88 MUT, and 14 (47%) carried a CXCR4 MUT. After ibrutinib treatment, median serum IgM levels declined from 4,370 to 1,513 mg/dL, bone marrow involvement declined from 65% to 20%, and hemoglobin level rose from 10.3 to 13.9 g/dL ( P < .001 for all comparisons). Overall (minor or more than minor) and major (partial or greater than partial) responses for all patients were 100% and 83%, respectively. Rates of major (94% v 71%) and very good partial (31 v 7%) responses were higher and time to major responses more rapid (1.8 v 7.3 months; P = 0.01) in patients with wild-type CXCR4 versus those with CXCR4 MUT, respectively. With a median follow-up of 14.6 months, disease in two patients (both with CXCR4 MUT) progressed. The 18-month, estimated progression-free survival is 92% (95% CI, 73% to 98%). All patients are alive. Grade 2/3 treatment-related toxicities in > 5% of patients included arthralgia (7%), bruising (7%), neutropenia (7%), upper respiratory tract infection (7%), urinary tract infection (7%), atrial fibrillation (10%), and hypertension (13%). There were no grade 4 or unexpected toxicities. Conclusion: Ibrutinib is highly active, produces durable responses, and is safe as primary therapy in patients with symptomatic WM. CXCR4 MUT status affects responses to ibrutinib.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2018.78.6426

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 182

Metadata

Authors
Treon, S. P., Gustine, J., Meid, K., Yang, G., Xu, L., Liu, X., Demos, M., Kofides, A., Tsakmaklis, N., Chen, J. G., Munshi, M., Chan, G., Dubeau, T., Raje, N., Yee, A., O’Donnell, E., Hunter, Z. R., & Castillo, J. J.
Venue
Journal of Clinical Oncology
Published
2018-09-20
Volume
36
Issue
27
Pages
2755-2761
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2884164278
Cited by
182
References
1
FWCI
10.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. https://app.cochat.ai/papers/10.1200/jco.2018.78.6426
The paper
Treon, S. P., Gustine, J., Meid, K., Yang, G., Xu, L., Liu, X., Demos, M., Kofides, A., Tsakmaklis, N., Chen, J. G., Munshi, M., Chan, G., Dubeau, T., Raje, N., Yee, A., O’Donnell, E., Hunter, Z. R., & Castillo, J. J. (2018). Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2018.78.6426

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.